ATE344246T1 - Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer - Google Patents

Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer

Info

Publication number
ATE344246T1
ATE344246T1 AT98962838T AT98962838T ATE344246T1 AT E344246 T1 ATE344246 T1 AT E344246T1 AT 98962838 T AT98962838 T AT 98962838T AT 98962838 T AT98962838 T AT 98962838T AT E344246 T1 ATE344246 T1 AT E344246T1
Authority
AT
Austria
Prior art keywords
alkoxyguanidine
aminoguanidine
heteroaryl
derivatives
protease inhibitors
Prior art date
Application number
AT98962838T
Other languages
English (en)
Inventor
Tianbao Lu
Bruce E Tomczuk
Thomas P Markotan
Colleen Siedem
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE344246T1 publication Critical patent/ATE344246T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT98962838T 1997-11-26 1998-11-25 Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer ATE344246T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6647597P 1997-11-26 1997-11-26
US6732497P 1997-12-05 1997-12-05
US7910798P 1998-03-23 1998-03-23

Publications (1)

Publication Number Publication Date
ATE344246T1 true ATE344246T1 (de) 2006-11-15

Family

ID=27370979

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98962838T ATE344246T1 (de) 1997-11-26 1998-11-25 Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer

Country Status (14)

Country Link
US (8) US6037356A (de)
EP (1) EP1036063B1 (de)
JP (1) JP2001524467A (de)
AR (1) AR016702A1 (de)
AT (1) ATE344246T1 (de)
AU (1) AU751412B2 (de)
BR (1) BR9815325A (de)
CA (1) CA2311969A1 (de)
DE (1) DE69836346T2 (de)
EA (1) EA004180B1 (de)
ES (1) ES2274587T3 (de)
PL (1) PL340560A1 (de)
TW (1) TWI222441B (de)
WO (1) WO1999026926A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2311969A1 (en) * 1997-11-26 1999-06-03 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
CA2329929A1 (en) * 1998-04-24 1999-11-04 3-Dimensional Pharmaceuticals, Inc. Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors
EP1086122B1 (de) * 1998-06-11 2005-08-24 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Pyrazine protease inhibitore
US6458952B1 (en) * 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
EA005367B1 (ru) * 1999-05-19 2005-02-24 Фармация Корпорейшн Замещенные пиридоны, их применение, композиция и способ ингибирования тромботических состояний и способы профилактики и лечения
US6867217B1 (en) * 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6906068B1 (en) 1999-05-19 2005-06-14 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4 - triazinones useful as anticoagulants
US6908919B2 (en) * 1999-05-19 2005-06-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6653316B1 (en) * 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
WO2000073302A1 (en) 1999-05-27 2000-12-07 3-Dimensional Pharmaceuticals, Inc. Oxazaheterocycles as protease inhibitors
CA2379416A1 (en) * 1999-07-09 2001-01-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl protease inhibitors and diagnostic imaging agents
CA2384247A1 (en) 1999-09-13 2001-03-22 3-Dimensional Pharmaceuticals, Inc. Azacycloalkanone serine protease inhibitors
EP1127884A1 (de) * 2000-02-26 2001-08-29 Aventis Pharma Deutschland GmbH Neue Malonsäure Derivaie, Verfahren zu ihrer Herstellung, ihre Verwendung als Inhibitor der Faktor XA Aktivtät und pharmazeutische Zusammensetzungen diese enthaltend
US6660885B2 (en) * 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
US6693121B2 (en) 2000-04-05 2004-02-17 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
PT1268463E (pt) * 2000-04-05 2005-05-31 Pharmacia Corp 4-pironas substituidas com arilo e heteroarilo policiclicos uteis para a inibicao selectiva da cascata de coagulacao
US6686484B2 (en) 2000-04-17 2004-02-03 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
AU2001217827A1 (en) * 2000-05-18 2001-11-26 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
EP1303510A2 (de) * 2000-07-17 2003-04-23 3-Dimensional Pharmaceuticals, Inc. Cyclische oxyguanidin-pyrazinone als protease-hemmer
WO2002012207A1 (en) * 2000-08-04 2002-02-14 3-Dimensional Pharmaceuticals, Inc. Cyclic oxyguanidine protease inhibitors
US20020037897A1 (en) * 2000-08-07 2002-03-28 3-Dimensional Pharmaceuticals, Inc. Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
US6486174B2 (en) 2000-08-07 2002-11-26 3-Dimensional Pharmaceuticals, Inc. Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
UA75093C2 (en) * 2000-10-06 2006-03-15 Dimensional Pharm Inc Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
WO2002042272A2 (en) 2000-11-20 2002-05-30 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US20030236257A1 (en) * 2001-04-04 2003-12-25 South Michael S. Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the cogulation cascade
DE10133786A1 (de) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis
US20040106626A1 (en) * 2001-10-03 2004-06-03 Pharmacia Corporation 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade
US20040082585A1 (en) * 2001-10-03 2004-04-29 Pharmacia Corporation Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
JP2005519866A (ja) 2001-10-03 2005-07-07 ファルマシア・コーポレーション 凝固カスケードの選択阻害に有用な６員複素環式化合物
EP1432687A2 (de) * 2001-10-03 2004-06-30 Pharmacia Corporation Substitutierte fünfgliedrige polyzyclischen vebindungen für die selektive hemmung der koagulationskaskade
AU2002364713A1 (en) 2001-12-04 2003-06-17 Corvas International, Inc. Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation
EP1569912B1 (de) 2002-12-03 2015-04-29 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidinderivate als faktor vii-a hemmer
ATE432703T1 (de) 2003-04-10 2009-06-15 Ortho Mcneil Pharm Inc Substituierte phenylacetamide und ihre anwendung als protease inhibitoren
WO2005110988A1 (en) * 2004-05-07 2005-11-24 Janssen Pharmaceutica, N.V. Pyridone compounds as inhibitors of bacterial type iii protein secretion systems
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US20050281799A1 (en) 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
WO2006014567A2 (en) 2004-07-08 2006-02-09 Pneumrx, Inc. Pleural effusion treatment device, method and material
WO2007127392A2 (en) * 2006-04-27 2007-11-08 Pronovost Allan D Devices and methods for collecting oral samples of enriched serous fluid
US7758001B2 (en) * 2006-09-13 2010-07-20 Premier Mounts Mount with magnetic attachment and automatic safety latching
WO2008036763A2 (en) * 2006-09-20 2008-03-27 Pneumrx, Inc. Tissue adhesive compositions and methods thereof
US7591075B2 (en) 2006-09-28 2009-09-22 Techtronic Power Tools Technology Limited Self-leveling mechanism
SG174809A1 (en) 2007-05-03 2011-10-28 Intermune Inc Macrocyclic compounds useful as inhibitors of hepatitis c virus
EP2164325B1 (de) 2007-05-31 2013-04-24 Shionogi&Co., Ltd. Oxyiminoverbindungen und ihre verwendung
ES2408159T3 (es) 2008-06-11 2013-06-18 Shionogi & Co., Ltd. Compuestos de oxicarbamoilo y su utilización
EP2434290B1 (de) 2009-05-20 2016-02-10 Sekisui Medical Co., Ltd. Mittel zur verlängerung der blutgerinnungszeit
US8349832B2 (en) * 2009-09-02 2013-01-08 Canthera Therapeutics Compounds and compositions for treating cancer
US8318737B2 (en) 2009-09-02 2012-11-27 Canthera Therapeutics Inc. Compounds and compositions for treating cancer
ES2654440T3 (es) 2010-12-21 2018-02-13 The Medicines Company (Leipzig) Gmbh Inhibidores de serina proteasa de tipo tripsina, su preparación y uso como inhibidores selectivos de los factores de coagulación IIa y Xa
EP2658580A4 (de) * 2010-12-31 2014-07-23 Corridor Pharmaceuticals Inc Arginasehemmer und verwendungsverfahren
US9788539B2 (en) 2011-05-17 2017-10-17 Velico Medical, Inc. Platelet protection solution having beta-galactosidase and sialidase inhibitors
WO2012158983A2 (en) 2011-05-17 2012-11-22 Qiyong Peter Liu Improved platelet storage using a sialidase inhibitor
EP2903430A1 (de) 2012-10-05 2015-08-12 Velico Medical, Inc. Plättchenadditivlösung mit beta-galactosidase-inhibitor
WO2014120886A1 (en) 2013-01-30 2014-08-07 Velico Medical, Inc. Platelet additive solution having a self-assembling hydrogel-forming peptide
US20150365084A1 (en) * 2014-06-13 2015-12-17 Infineon Technologies Austria Ag Circuits and methods for operating a circuit

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097472A (en) 1974-11-08 1978-06-27 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
SU328634A1 (ru) 1971-01-05 1978-01-05 Butyrin V G Устройство дл забора проб крови у животных
SU938739A3 (ru) 1977-01-19 1982-06-23 Мицубиси Кемикал Индастриз Лимитед(Фирма) Способ получени N -арилсульфонил-L-аргининамидов или их солей
US4418052A (en) * 1980-08-12 1983-11-29 Wong Dennis W Diagnostic compositions and method for radiologic imaging of fibrinogen deposition in the body
US4980148A (en) * 1985-02-06 1990-12-25 Mallinckrodt, Inc. Methods for enhancing magnetic resonance imaging
US5011686A (en) * 1987-09-21 1991-04-30 Creative Biomolecules, Inc. Thrombus specific conjugates
ZA897515B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US5024829A (en) * 1988-11-21 1991-06-18 Centocor, Inc. Method of imaging coronary thrombi
US5656600A (en) * 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5658885A (en) * 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
GB9318637D0 (en) 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors
US5466811A (en) * 1994-07-18 1995-11-14 Merck & Co., Inc. Dioxolenylmethyl carbamates pro moieties for amine drugs
US5656645A (en) * 1994-12-13 1997-08-12 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
DE69526677T2 (de) * 1994-12-13 2002-12-05 Corvas International, Inc. Aromatische heterocyclische derivate als enzyminhibitoren
US5658930A (en) * 1994-12-13 1997-08-19 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
AU703744B2 (en) * 1995-06-27 1999-04-01 Merck & Co., Inc. Pyridinone-thrombin inhibitors
AU720616B2 (en) * 1996-02-22 2000-06-08 Merck & Co., Inc. Pyridinone thrombin inhibitors
NZ332073A (en) 1996-03-29 2000-05-26 Dimensional Pharm Inc Substituted hydrazinecarboximines as non-peptidic protease inhibitors
TW499412B (en) 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
CA2311969A1 (en) * 1997-11-26 1999-06-03 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
EP1086122B1 (de) * 1998-06-11 2005-08-24 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Pyrazine protease inhibitore
WO2000073302A1 (en) 1999-05-27 2000-12-07 3-Dimensional Pharmaceuticals, Inc. Oxazaheterocycles as protease inhibitors
CA2379416A1 (en) 1999-07-09 2001-01-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl protease inhibitors and diagnostic imaging agents
US6236492B1 (en) * 1999-08-03 2001-05-22 Crystal Corporation Electrode with a balanced centroid, soft edges and an apodization ratio greater than one

Also Published As

Publication number Publication date
US6706021B2 (en) 2004-03-16
US6037356A (en) 2000-03-14
DE69836346D1 (de) 2006-12-14
US6350764B2 (en) 2002-02-26
US6472399B2 (en) 2002-10-29
US20020086872A1 (en) 2002-07-04
US20060211719A1 (en) 2006-09-21
US20030087921A1 (en) 2003-05-08
US20030225115A1 (en) 2003-12-04
PL340560A1 (en) 2001-02-12
ES2274587T3 (es) 2007-05-16
EA004180B1 (ru) 2004-02-26
TWI222441B (en) 2004-10-21
US6245763B1 (en) 2001-06-12
BR9815325A (pt) 2001-12-26
AR016702A1 (es) 2001-07-25
WO1999026926A1 (en) 1999-06-03
CA2311969A1 (en) 1999-06-03
AU751412B2 (en) 2002-08-15
US6566379B1 (en) 2003-05-20
JP2001524467A (ja) 2001-12-04
EA200000578A1 (ru) 2001-02-26
US20040106633A1 (en) 2004-06-03
US7402586B2 (en) 2008-07-22
EP1036063A1 (de) 2000-09-20
US7029654B2 (en) 2006-04-18
US20020007070A1 (en) 2002-01-17
DE69836346T2 (de) 2007-05-24
AU1799199A (en) 1999-06-15
EP1036063B1 (de) 2006-11-02

Similar Documents

Publication Publication Date Title
ATE344246T1 (de) Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer
ATE302193T1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE59703869D1 (de) Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren
ATE277895T1 (de) 4-brom or 4-iod-phenylamino- benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
ATE277902T1 (de) Amidinoderivate und ihre verwendung als thrombininhibitoren
ATE214693T1 (de) Aminoguanidine und alkoxyguanidine als protease- hemmer
ATE299503T1 (de) Pyridin-3-carbonsäurederivate und ihre verwendung als zwischenprodukte
DE60139477D1 (de) 2-cyanopyrrolidin-derivate und ihre verwendung als arzneimittel
DE69818248D1 (de) Chinolin- und chinazolin-derivate als crf antagonisten
DE69824418D1 (de) Substituierte quinazolin-derivate und ihre verwendung als tyrosin-kinase inhibitoren
ATA5422000A (de) Oximderivate und ihre verwendung als latente säuren
ATE269701T1 (de) Gyrase-inhibitoren und ihre verwendung
DE60133897D1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
DE69820397D1 (de) Ätzmittel und ihre Verwendung
DE60219068D1 (de) Substituierte 2-amino-zykloalkankarboxamide und ihre verwendung als zysteinprotease-inhibitoren
ATE329906T1 (de) Substituierte 2-anilino-benzimidazole und ihre verwendung als nhe-inhibitoren
DE69811223D1 (de) N-triazolyl-2-indolcarbonsäureamide und ihre verwendung als cck-a agonisten
DE60037183D1 (de) Neue amidinbenzylamin-derivate und ihre verwendung als thrombin-inhibitoren
DE69902387D1 (de) Oxadiazolinderivate und ihre verwendung als insektizide
DE50008549D1 (de) Triazolotriazinone und ihre verwendung
ATE209626T1 (de) Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren
DE69811018D1 (de) Triazol-Derivate und ihre Verwendung als antimykotische Mittel
DE50004274D1 (de) Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one und ihre verwendung als lipase-hemmer
DE69832902D1 (de) Oromukosal-zytokin-zusammensetzungen und ihre verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties